Core Viewpoint - The company has established an AI professional team and server infrastructure to enhance innovation in drug development, process design, intelligent manufacturing, and quality control [1] Group 1: AI Integration - The company is accelerating the application of AI across various stages of its operations, including drug research and development [1] - There is an ongoing effort to collaborate with leading external AI technology platforms and research institutions to promote deep integration and intelligent upgrades of AI technology throughout the company's entire industry chain [1]

Core Viewpoint - The implementation of the negative list for data export in free trade zones presents both opportunities and challenges for enterprises, facilitating cross-border data flow while ensuring compliance with regulations [1] Group 1: Policy Implementation and Impact - The Shanghai Free Trade Zone (FTZ) has initiated the first national practice exchange event for the negative list of data export, involving various departments and over 50 key enterprises [1] - The negative list allows enterprises to report data export activities after usage, eliminating prior approval processes and potentially exempting them from evaluations or filings [2] - The introduction of the negative list has significantly reduced compliance costs for enterprises, with thresholds for sensitive personal information raised from 10,000 to 100,000 individuals [2] Group 2: Support and Guidance for Enterprises - A data cross-border service center has been established in the Shanghai FTZ, conducting nearly 20 policy briefings and providing one-on-one consultations for over 1,000 enterprises [3] - An expert group has been formed to support data cross-border facilitation, including professionals from various organizations to assist enterprises in expanding overseas markets [3] - The city and district data cross-border teams are continuously updating operational guidelines and providing professional training to better address enterprise needs [3] Group 3: Events and Activities - During the National Cybersecurity Awareness Week, seven district-level activities will be held, including policy practice exchanges and cybersecurity competitions [4]

Core Viewpoint - Bayer and Tsinghua University have signed the sixth phase of their strategic research cooperation agreement, aiming to enhance the translation of basic research into new drug development across multiple key areas such as oncology, cardiovascular and renal diseases, neurology, rare diseases, and immunology [1][3]. Group 1: Research Collaboration - Bayer will continue to fund joint research projects for the next three years and reward Tsinghua University scientists who make significant contributions in life sciences and drug innovation [2]. - Since 2009, Bayer has collaborated with Tsinghua University on 75 joint research projects, resulting in 15 co-authored papers published in renowned international academic journals [3]. - The establishment of the "Bayer Research Transformation Fund" in 2022 has supported 9 projects in the past three years, further enhancing the translation of early research outcomes [3]. Group 2: Innovation and Development - Bayer's collaboration with Tsinghua University is seen as a model for cooperation between multinational pharmaceutical companies and local academic institutions in China, contributing to significant advancements in scientific research and drug development [4]. - The partnership aims to address global health challenges and accelerate the conversion of basic research into drug applications, marking an important milestone in their long-term strategic cooperation [4]. - Bayer emphasizes its commitment to local research collaboration and supports the transformation of original innovations and new drug development in China [5]. Group 3: Local Ecosystem Engagement - As China becomes a major source of biotechnological innovation, Bayer is actively integrating into the local innovation ecosystem and exploring open innovation with Chinese partners [6]. - Bayer Co.Lab, set to open in September 2024, aims to empower 10 to 15 local startups focusing on cutting-edge innovations in oncology, cardiovascular and renal diseases, and cell and gene therapies [6]. - Bayer has entered a global licensing agreement with a Chinese biotechnology company for a selective oral small molecule PRMT5 inhibitor targeting MTAP-deficient tumors, with the first patient already recruited for Phase I clinical trials [6].